O.R.C.A.pharm

ORCApharm is a German biotechnology company and a subsidiary of ITM Isotope Technologies Munich SE, specializing in the development of innovative radiopharmaceuticals for oncology. The company focuses on radioligand therapy (RLT), a precision medicine approach that combines therapeutic radioisotopes with targeting molecules to deliver radiation directly to cancer cells. Their lead programs utilize high-purity medical isotopes, such as Lutetium-177 and Actinium-225, to treat high-unmet-need indications including metastatic prostate cancer. ORCApharm leverages the extensive manufacturing and supply chain infrastructure of its parent company to ensure reliable access to medical radioisotopes. By integrating advanced targeting ligands with potent alpha and beta emitters, the company aims to improve clinical outcomes for patients with advanced malignancies.